Metoprolol-CYP2D6 PBPK Model

[SRuedesh]

Dear OSP-community,

We have been working on a PBPK model of the CYP2D6 substrate metoprolol. The model is able to predict and describe the effect of CYP2D6 drug-gene interactions on the pharmacokinetics of (R)-metoprolol, (S)-metoprolol and their major active metabolite α-hydroxymetoprolol.

The manuscript, including comprehensive supplementary materials, has been published online in Pharmaceutics [1] and the metoprolol PK-Sim model (including metoprolol enantiomers and metabolite α-hydroxymetoprolol) is available here.

Related publication:
[1] Rüdesheim, S.; Wojtyniak, J.-G.; Selzer, D.; Hanke, N.; Mahfoud, F.; Schwab, M.; Lehr, T. Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics 2020, 12, 1200.

Kind regards,
Simeon